Clinical Trials Browser

Phase 1 × Myelodysplastic Syndromes × fostamatinib × Clear all

NCT05030675 2025-02-13

Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic